Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Breast Neoplasms 23Ovarian Neoplasms 19Triple Negative Breast Neoplasms 17Endometrial Neoplasms 16Lung Neoplasms 15Parkinson Disease 4, Autosomal Dominant Lewy Body 12Fallopian Tube Neoplasms 11Squamous Cell Carcinoma of Head and Neck 9Neoplasm Metastasis 9Neoplasms 6Esophageal Neoplasms 6Adenocarcinoma Of Esophagus 6Stomach Neoplasms 4Melanoma 4Esophageal Squamous Cell Carcinoma 4Cholangiocarcinoma 4Uterine Cervical Neoplasms 3Colorectal Neoplasms 3Carcinoma 3Uterine Neoplasms 2Urinary Bladder Neoplasms 2Peritoneal Neoplasms 2Pathologic Complete Response 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Ovarian Epithelial 2Brenner Tumor 2Anatomic Stage I Breast Cancer AJCC v8 2Advanced Solid Tumour 2

Interventions

Rituximab 2pomalidomide 1dehydroftorafur 1Watchful Waiting 1Vincristine 1Taxes 1Radiotherapy, Intensity-Modulated 1Prednisone 1Platinum 1Paclitaxel 1Nivolumab 1Gemcitabine 1Fluorouracil 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Epstein-Barr Virus Infections × Paclitaxel × 30 days × Clear all
NCT02135042 2026-05-07

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

NRG Oncology

Phase 2/3 Active not recruiting
685 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡